Package 70771-1753-9

{"route": ["ORAL"], "spl_id": "6ad07423-8166-4871-81cd-c1e6449410e6", "openfda": {"nui": ["N0000185008", "N0000185007", "N0000182137", "N0000190114", "N0000185503"], "unii": ["MVR3JL3B2V"], "rxcui": ["1300791", "1300801"], "spl_set_id": ["461b2b94-205a-4860-9cb4-d30267ada9df"], "pharm_class_epc": ["beta3-Adrenergic Agonist [EPC]"], "pharm_class_moa": ["Adrenergic beta3-Agonists [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "manufacturer_name": ["Zydus Lifesciences Limited"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "100 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1753-1)", "package_ndc": "70771-1753-1", "marketing_start_date": "20240123"}, {"sample": false, "description": "30 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1753-3)", "package_ndc": "70771-1753-3", "marketing_start_date": "20240123"}, {"sample": false, "description": "90 TABLET, EXTENDED RELEASE in 1 BOTTLE (70771-1753-9)", "package_ndc": "70771-1753-9", "marketing_start_date": "20240123"}], "brand_name": "Mirabegron", "product_id": "70771-1753_6ad07423-8166-4871-81cd-c1e6449410e6", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Adrenergic beta3-Agonists [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "beta3-Adrenergic Agonist [EPC]"], "product_ndc": "70771-1753", "generic_name": "Mirabegron", "labeler_name": "Zydus Lifesciences Limited", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Mirabegron", "active_ingredients": [{"name": "MIRABEGRON", "strength": "50 mg/1"}], "application_number": "ANDA209488", "marketing_category": "ANDA", "marketing_start_date": "20240123", "listing_expiration_date": "20261231"}